GlassScriptPhysician profile
Jagadeesh Ramdas
NPI 1932164977
$6,321.97
in general payments reported to CMS, 2019-2025
11 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,397 · 2020: $350 · 2021: $1,125 · 2024: $400 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,325 · Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,325.00 |
| Food and Beverage | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $3,194.31 | 2019 | |
| Genzyme Corporation | $1,150.00 | 2019-2021 | |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Astrazeneca Pharmaceuticals LP | $400.00 | 2024 | Imfinzi |
| Sanofi-Aventis U.S. LLC | $350.00 | 2021 | |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Syndax Pharmaceuticals, INC. | $124.99 | 2025 | Revuforj |
| Kyowa Kirin, INC. | $107.68 | 2019 | |
| Astellas Pharma US INC | $69.99 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jagadeesh Ramdas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.